Loading...
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells
Synovial sarcoma (SS) is a rare high-grade malignant mesenchymal tumour with a relatively poor prognosis despite intensive multimodal therapy. Although pazopanib, a multi-kinase inhibitor, is often used for advanced SS, most cases eventually become resistant to pazopanib. In the present study, we in...
Na minha lista:
| Udgivet i: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5368598/ https://ncbi.nlm.nih.gov/pubmed/28350009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep45332 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|